WOODCLIFF LAKE, N.J. and NEW YORK, Nov. 24 /PRNewswire/ -- Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug Application (NDA) for once daily 23 mg Aricept® (donepezil HCl extended release) tablets for the treatment of moderate to severe Alzheimer's disease (AD). This new higher dose formulation contains 23 mg of donepezil HCl in an extended release, matrix-type tablet with a delivery system that allows for gradual release of the drug. The NDA is based on a head-to-head clinical study comparing the 23 mg Aricept extended release tablet to the currently marketed once daily 10 mg Aricept® (donepezil HCl) immediate release tablet. More than 1400 patients with moderate to severe Alzheimer's disease were enrolled in this global study.
The Australian Psychological Society (APS), Australia's largest allied health representative body, strongly supports the call from Allied Health Professions Australia (AHPA) for the allied health sector to be involved in the design, governance and delivery of the Government's new primary health care system...
WASHINGTON, Dec. 7 /PRNewswire/ -- Nationally-known expert Kenneth Doka, Senior Bereavement Consultant to Hospice Foundation of America (HFA), will host a discussion of the need for, and role of, bereavement camps as an intervention for children, adolescents, and their families during Hospice Foundation of America's (HFA's) live online webinar on Monday, February 1, from 1pm -- 2:30pm ET. Dr. Doka will be joined by Sherry Schachter, Director of Camp Courageous in New York; Angela Hamblen, Director of Camp Good Grief in Tennessee; and Bonnie Carroll, Executive Director of TAPS, which offers support to those suffering the loss of a military loved one.